CCIL researchers identify a testicular cancer target

January 10, 2025

Vol.51 No.01

DOWNLOAD PDF TABLE OF CONTENTS

Cancer Center at Illinois member Michael Spinella and his lab are investigating an approach for killing testicular cancer cells with epigenetic drugs, or “epidrugs,” that target the polycomb pathway.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Oana Danciu named Big Ten CRC steering committee chair

Oana Danciu, associate director for clinical research at the University of Illinois Cancer Center, was appointed by the Big Ten Cancer Research Consortium as chair of its steering committee.

June 14, 2024

Vol.50 No.24

In Brief

Cancer Center at Illinois researchers receive $650,000 Convergence Accelerator Grant from NSF

A research team led by Cancer Center at Illinois has received a $650,000 phase I grant from the National Science Foundation’s Convergence Accelerator.

March 15, 2024

Vol.50 No.11

Clinical Roundup

Cancer Center at Illinois Chan Lab develops therapeutic to reduce side effects of cancer treatment

Cancer Center at Illinois member Jeff Chan, associate professor of chemistry, recently published research demonstrating the development of an activatable cancer therapeutic to help eliminate the side effects of traditional chemotherapies.

March 15, 2024

Vol.50 No.11